3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
6
Neoplasm Metastasis
2
Thrombocytopenia
1
Smoking
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neutropenia
1
Mesothelioma, Malignant
1
Mesothelioma
1
Cytopenia
1
Anemia
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
44
Carboplatin
17
Pemetrexed
14
Paclitaxel
13
Cisplatin
13
lenvatinib
5
Etoposide
5
Docetaxel
5
epacadostat
4
Gemcitabine
4
Albumin-Bound Paclitaxel
4
durvalumab
3
Nivolumab
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
olaparib
2
Saline Solution
2
Immune Checkpoint Inhibitors
2
Dexamethasone
2
Acetaminophen
2
sacituzumab govitecan
1
ribociclib
1
patritumab deruxtecan
1
osimertinib
1
etoposide phosphate
1
efineptakin alfa
1
cemiplimab
1
camrelizumab
1
avelumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Vitamin B 12
×
Thoracic
×
Clear all
NCT03950674
2024-06-10
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3
Completed
40 enrolled
20 charts